CCL22 and Alzheimer disease: The study performed by Kakinuma et al., including 45 patients with AD, 25 patients with PsO and 25 healthy controls, revealed that serum levels of CCL22/MDC in AD patients were significantly higher than those in healthy controls and PsO patients [36].